Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …

Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …

OBJECTIVE To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in
TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials. gov) participants with type 2 …

Aim The present systematic review aimed to summarize the available evidence from
published randomized controlled trials (RCTs) regarding the effect of tirzepatide on …

Background Change in albuminuria has strong biological plausibility as a surrogate
endpoint for progression of chronic kidney disease, but empirical evidence to support its …

Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …

Background Many antihyperglycaemic drugs, including insulin, are primarily cleared by the
kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long …

Aims/hypothesis Insulin is the primary treatment for type 1 diabetes. However, alternative
glucose-lowering therapies are used adjunctively, but importantly are off-label in type 1 …

In parallel with the type 2 diabetes pandemic, diabetic kidney disease has become the
leading cause of end-stage renal disease worldwide, and is associated with high …

Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …